Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Identification and prioritisation of risks in a hospital pharmacy using healthcare failure mode and effect analysis.

Castro Vida MÁ, Martínez de la Plata JE, Morales-Molina JA, Pérez Lázaro JJ, Acosta Robles P.

Eur J Hosp Pharm. 2019 Mar;26(2):66-72. doi: 10.1136/ejhpharm-2017-001242. Epub 2017 Sep 27.

PMID:
31157102
2.

FCGR2A/FCGR3A Gene Polymorphisms and Clinical Variables as Predictors of Response to Tocilizumab and Rituximab in Patients With Rheumatoid Arthritis.

Jiménez Morales A, Maldonado-Montoro M, Martínez de la Plata JE, Pérez Ramírez C, Daddaoua A, Alarcón Payer C, Expósito Ruiz M, García Collado C.

J Clin Pharmacol. 2019 Apr;59(4):517-531. doi: 10.1002/jcph.1341. Epub 2018 Nov 20.

PMID:
30457672
3.

[Biosimilars, the journey has begun].

Martos-Rosa A, Martínez-de la Plata JE, Morales-Molina JA, Fayet-Pérez A, Acosta-Robles PJ.

Farm Hosp. 2015 Mar 1;39(2):114-7. doi: 10.7399/fh.2015.39.2.8789. Spanish.

4.

Bosentan and oral anticoagulants in HIV patients: what we can learn of cases reported so far.

Morales-Molina JA, Martínez-de la Plata JE, Urquízar-Rodríguez O, Molina-Arrebola MA.

Hematol Rep. 2011 Aug 31;3(2):e16. doi: 10.4081/hr.2011.e16. Epub 2011 Oct 10.

Supplemental Content

Loading ...
Support Center